Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director | June 01, 2022 | June 03, 2022 |
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Director | February 04, 2021 | February 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date June 01, 2022 · Filed June 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,312 |
Reported balance
After 2022-06-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-06-01 · Grant · Acquired 4,312 · Balance 4,312 F1: Includes 4,312 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.29 · Expires 2032-06-01 | Direct | 11,796 |
Reported balance
After 2022-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-01 · Grant · Acquired 11,796 · Balance 11,796 F2: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 4,312 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
F2: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 1, 2022.
Viridian Therapeutics, Inc.\DE
Report date February 04, 2021 · Filed February 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.50 · Expires 2031-02-04 | Direct | 25,000 |
Reported balance
After 2021-02-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-04 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vest monthly over a three year period, subject to Reporting Person's continued service on the Board. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vest monthly over a three year period, subject to Reporting Person's continued service on the Board.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2022 Filed Jun 3, 2022 16:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 11,796 | $0.00 Strike: $20.29 | $0.00 |
DisclosureSEC source: 0001567619-22-012310 · doc1.xml · derivative · entry 2 TURNER JOSEPH L · CIK 0001266129 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,796 Underlying: Common Stock · 11,796 shares Expires 2032-06-01 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 1, 2022. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 16:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 4,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-012310 · doc1.xml · nonDerivative · entry 1 TURNER JOSEPH L · CIK 0001266129 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,312 F1 · balance_after: Includes 4,312 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 16:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 13,391 | $0.00 Strike: $27.77 | $0.00 |
DisclosureSEC source: 0001567619-21-012028 · doc1.xml · derivative · entry 1 TURNER JOSEPH L · CIK 0001266129 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,391 Underlying: Common Stock · 13,391 shares Expires 2031-06-09 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of (i) the first anniversary of June 9, 2021 or (ii) the next Annual Meeting following June 9, 2021, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 17:41 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantDirector Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $20.50 | $0.00 |
DisclosureSEC source: 0000899243-21-005209 · doc4.xml · derivative · entry 1 TURNER JOSEPH L · CIK 0001266129 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-02-04 F1 · derivative.exercise_date: The option vest monthly over a three year period, subject to Reporting Person's continued service on the Board. Read SEC document |
| May 21, 2020 Filed May 22, 2020 17:21 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-20-031837 · doc4.xml · derivative · entry 1 TURNER JOSEPH L · CIK 0001266129 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-05-20 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 19:56 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-20-006135 · doc4.xml · derivative · entry 1 TURNER JOSEPH L · CIK 0001266129 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2030-01-30 F1 · date: Stock options were granted to the Reporting Person on January 30, 2020 in connection with the Reporting Person's appointment to the Issuer's Board of Directors on January 30, 2020. F2 · derivative.exercise_date: The option vests as to 1/3 of the total shares on each of January 30, 2021, January 30, 2022 and January 30, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 17:18 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001209191-19-038579 · doc4.xml · derivative · entry 1 TURNER JOSEPH L · CIK 0001266129 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 16:49 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $6.46 | $0.00 |
DisclosureSEC source: 0001209191-18-039897 · doc4.xml · derivative · entry 1 TURNER JOSEPH L · CIK 0001266129 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-06-26 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 17:23 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $12.06 | $0.00 |
DisclosureSEC source: 0001209191-17-042573 · doc4.xml · derivative · entry 1 TURNER JOSEPH L · CIK 0001266129 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-27 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.